Literature DB >> 10953980

Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia.

Z Beck1, A Kiss, F D Tóth, J Szabó, A Bácsi, E Balogh, A Borbély, B Telek, E Kovács, E Oláh, K Rak.   

Abstract

Using the single-strand conformation polymorphism and heteroduplex analyses, the P53 and RB genes were analyzed in cell samples from twenty-eight patients with chronic myeloid leukemia (CML) both at diagnosis and at the onset of accelerated phase (AP) of the disease. No alterations of the P53 or RB genes were found in any of the chronic phase (CP) samples. Structural abnormalities of the P53 gene were observed in ten of twenty-eight AP samples within exons 4, 5, 7 and 9. Of the ten cases of AP disease with altered P53 genes, five patients also suffered from the deletion of the other allele. Alterations of the RB gene could be detected in six AP samples, and aberrant band patterns were found in the analysis of exons 2, 3, 4, 6, 7, 13, 14, 17, 21 and 26. Among the six AP samples with structural abnormalities of the RB gene, two showed the loss of the other allele. It is of note that alterations of both P53 and RB genes were observed in two AP samples. Our data strongly suggest that abnormalities of the P53 and RB genes and acceleration of CML are linked events in some cases of AP.

Entities:  

Mesh:

Year:  2000        PMID: 10953980     DOI: 10.3109/10428190009059278

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Programmed cell death 4 and BCR-ABL fusion gene expression are negatively correlated in chronic myeloid leukemia.

Authors:  Xia Zhang; Riming Liu; Baohua Huang; Xiaolu Zhang; Weijuan Yu; Cuixia Bao; Jie Li; Chengming Sun
Journal:  Oncol Lett       Date:  2016-08-03       Impact factor: 2.967

2.  PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.

Authors:  Cong Peng; Yaoyu Chen; Zhongfa Yang; Haojian Zhang; Lori Osterby; Alan G Rosmarin; Shaoguang Li
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

3.  Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.

Authors:  Bing Z Carter; Po Yee Mak; Duncan H Mak; Vivian R Ruvolo; Wendy Schober; Teresa McQueen; Jorge Cortes; Hagop M Kantarjian; Richard E Champlin; Marina Konopleva; Michael Andreeff
Journal:  Oncotarget       Date:  2015-10-13

Review 4.  Aging and the rise of somatic cancer-associated mutations in normal tissues.

Authors:  Rosa Ana Risques; Scott R Kennedy
Journal:  PLoS Genet       Date:  2018-01-04       Impact factor: 5.917

5.  Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.

Authors:  Zhanglin Zhang; Zhiwei Chen; Mei Jiang; Shuyuan Liu; Yang Guo; Lagen Wan; Fei Li
Journal:  BMC Cancer       Date:  2019-10-08       Impact factor: 4.430

Review 6.  Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.

Authors:  Luana Bavaro; Margherita Martelli; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2019-12-05       Impact factor: 5.923

Review 7.  Treatment selection after imatinib resistance in chronic myeloid leukemia.

Authors:  Elias Jabbour; Jorge Cortes; Hagop Kantarjian
Journal:  Target Oncol       Date:  2009-01-30       Impact factor: 4.493

8.  Intronic SNPs of TP53 gene in chronic myeloid leukemia: Impact on drug response.

Authors:  K Sailaja; V R Rao; Satish Yadav; R Rajasekhar Reddy; D Surekha; D Nageswara Rao; D Raghunadharao; S Vishnupriya
Journal:  J Nat Sci Biol Med       Date:  2012-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.